Divi's Labs hits 52-week high after record Q2; Elara at 'Sell'
FROM THE WIRE · THEHINDUBUSINESSLINE.COM
Divi’s Laboratories hits a 52-week high on strong Q2 results, with brokerages bullish amid revenue growth and Elara Securities’ Sell note.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAn Indian pharma stock rises to a 52-week high after strong results, against a Sell rating.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Divi's Laboratories hit a 52-week high.
- 02Q2 results were described as record.
- 03Elara Securities maintains a Sell rating.